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The insulin receptor substrate (IRS) proteins are cytoplasmic adaptors that organize signaling complexes
downstream of activated cell surface receptors. Here, we show that IRS-1 and IRS-2, despite significant
homology, play critical yet distinct functions in breast cancer, and we identify specific signaling pathways that
are influenced by IRS-1 using the polyoma virus middle-T (PyV-MT) transgenic mouse model of mammary
carcinoma and Irs-1 null (Irs1/) mice. The absence of Irs-1 expression enhanced metastatic spread signif-
icantly without a significant effect on primary tumor growth. Orthotopic transplant studies revealed that the
increased metastatic potential of Irs1-deficient tumor cells is cell autonomous. Mammary tumors that devel-
oped in PyV-MT::Irs1/ mice exhibited elevated Irs-2 function and enhanced phosphatidylinositol 3-kinase/
Akt/mTor activity, suggesting that one mechanism by which Irs-1 impedes metastasis is to suppress Irs-2-
dependent signaling. In support of this mechanism, reduction of Irs-2 expression in Irs1/ tumor cells
restored mTor signaling to wild-type levels. PyV-MT::Irs1/ tumors also exhibited a significant increase in
vascular endothelial growth factor expression and microvessel density, which could facilitate their dissemi-
nation. The significance of our findings for human breast cancer is heightened by our observation that Irs-1
is inactivated in wild-type, metastatic mammary tumors by serine phosphorylation. Collectively, our findings
reveal that inactivation of IRS-1 enhances breast cancer metastasis and support the novel hypothesis that
IRS-1 has metastasis suppressor functions for breast cancer.
The insulin receptor substrate (IRS) proteins are cytoplas-
mic docking proteins that function as essential signaling inter-
mediates downstream of activated cell surface receptors, in-
cluding the insulin, insulin-like growth factor 1 (IGF-1),
prolactin, growth hormone (GH), and vascular endothelial
growth factor (VEGF) receptors, members of the integrin re-
ceptor family, and select cytokine receptors (38, 68, 70, 78, 81,
85). The IRS proteins are recruited to receptors through pleck-
strin homology and phosphotyrosine-binding domains in
their N termini and mediate their functions by organizing
signaling complexes at sites of receptor activation (81).
Upon binding they are phosphorylated on tyrosine residues
in their C termini, creating multiple phosphotyrosine bind-
ing motifs that recruit downstream effectors, including phos-
phatidylinositol 3-kinase (PI3K), Grb-2, Fyn, and Shp-2 to
initiate intracellular signaling cascades (81). The IRS pro-
teins were originally identified as substrates of the insulin
receptor, and they have been predominantly studied for
their role in metabolic signaling (81). Although the IRS
proteins are highly homologous, there is evidence for unique
functions for each of the four IRS family members. Irs-1 null
mice are born small and remain runted throughout life, and
these mice develop insulin resistance. However, Irs-1 null
mice do not develop diabetes, because they maintain normal
numbers of pancreatic beta cells (3). In contrast, Irs-2 null
mice are a normal size at birth but exhibit brain defects and
develop early-onset diabetes due to a combination of pe-
ripheral insulin resistance and beta-cell failure (66, 83, 84).
Irs-3 null mice are phenotypically normal, and Irs-4 null
mice have mild reproductive and insulin sensitivity defects
(16, 42).
IRS-1 and IRS-2 are the IRS family members that are ex-
pressed in normal mammary epithelial tissue, both in humans
and in mice, and in breast cancer (37, 52). To date, more is
known regarding the role of IRS-2 in breast cancer than that of
IRS-1. The importance of IRS-2 for breast cancer progression
was first suggested by the fact that the IGF-1 receptor no
longer promotes mitogenesis but it is still required for metas-
tasis in estrogen receptor-negative (ER) breast carcinoma
cell lines which lack or have decreased IRS-1 expression but
retain IRS-2 expression (15). In these cell lines, which signal
predominantly through IRS-2, IGF-1 stimulates breast carci-
noma cell motility (6, 14, 33, 86). IRS-2 is also an essential
intermediate in the activation of PI3K and promotion of breast
carcinoma invasion by the 64-integrin receptor (70). The
most compelling data that support a critical role for IRS-2 in
breast cancer were provided by our study that examined the
impact of Irs-2 deficiency on the polyoma virus middle-T (PyV-
MT) mouse model of mammary tumor progression (52). We
found that Irs-2-deficient mice did not exhibit differences in
mammary tumor onset or growth compared to mice with a
wild-type (WT) genetic background. However, they did exhibit
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significantly reduced rates of metastasis (52). Mammary tumor
cells derived from the PyV-MT::Irs2/ mice also exhibited
attenuated invasion and cell survival. These findings not only
highlighted the importance of IRS-2 for breast cancer progres-
sion, but they also revealed that IRS-1 is not sufficient to
promote metastasis.
The inability of Irs-1 to compensate for the loss of Irs-2 in
mammary tumor metastasis in vivo supports the hypothesis
that IRS-1 functions in breast cancer in a manner distinct from
that of IRS-2. However, the existing data on IRS-1, which were
derived largely from studies on human breast carcinoma cell
lines, are conflicting and have not provided definitive insight
into the contribution of IRS-1 to breast cancer. For example,
suppression of IRS-1 expression in ER breast carcinoma cell
lines inhibits IGF-1-dependent proliferation and survival, sug-
gesting that IRS-1 plays a positive role in breast cancer (9, 53).
However, ER breast carcinoma cell lines, which express low
levels of IRS-1, are more invasive and metastatic than ER
cells (32, 70). In the current study, we examined rigorously the
role of Irs-1 in mammary tumorigenesis and progression and
investigated the specific pathways that are influenced by Irs-1
function. Our data reveal that loss of Irs-1 expression stimu-
lates metastatic spread significantly. The significance of our
findings for human breast cancer is heightened considerably by
our novel observation that Irs-1 is selectively inactivated in
metastatic mammary tumors.
MATERIALS AND METHODS
Mice. Female C57Bl/6, Irs1/ mice were generated previously and were bred
for 10 generations into the FVB genetic background (3). Female FVB Irs1/
mice were crossed with male FVB mice that were transgenic (/) for the
PyV-MT antigen under the control of the mouse mammary tumor virus pro-
moter (Jackson Labs) to generate PyV-MT/::Irs1/ male mice. Female
Irs1/ mice were bred to male PyV-MT/::Irs1/ mice, and female offspring
from this cross that were PyV-MT/ and were wild type for the Irs-1 allele
(PyV-MT) or homozygous null for the Irs-1 allele (PyV-MT::Irs1/) were saved
for further analysis. Genotyping was performed by PCR using oligonucleotides
specific for the Irs-1 gene (5-GCCAGGCACCAGCATCTTCG-3 and 5-TGG
CCGCTCCCGAATTCAAT-3), the neomycin gene (5-GCTACCCGTGATA
TTGCTGAAGAG-3), and as described previously for the PyV-MT transgene
(24). PyV-MT::Irs2/ female mice were generated as described previously (52).
Beginning at 15 days of age, the mice were palpated every 5 days to detect the
onset of mammary tumor development. At 75, 80, or 85 days, the tumors were
dissected and measured using calipers. The total tumor volume was determined
using the following formula: volume  (4/3)()(1/2  smaller diameter)2(1/2 
larger diameter). Portions of the tumors and the lungs were either snap frozen or
fixed in 10% buffered formalin. Blood was also collected at the time of sacrifice
(100 	l) and spun at 1,000 rpm for 10 min at 4°C to obtain serum.
To examine the ability of Irs-1-deficient PyV-MT mammary tumor cells to
grow and metastasize in a wild-type-Irs genetic background, PyV-MT and
PyV-MT::Irs1/ mammary tumor cells (2  106) were resuspended in Matrigel
(50 	l) and injected into the number 3 and number 8 thoracic mammary glands
of female nu/nu mice. At an equivalent tumor burden [tumor size determined
using the following formula: volume  width2  (length/2)], the tumors and
lungs were dissected and portions of each were either snap-frozen or fixed in
10% buffered formalin (50).
IHC. Formalin-fixed tissue was embedded in paraffin and sections were stained
either with hemotoxylin and eosin (H&E) or with antibodies for histology and
immunohistochemistry (IHC) analysis. For IHC, tissue sections were deparaf-
finized and rehydrated before endogenous peroxidase activity was quenched in
3% H2O2 for 5 min. For detection of estrogen receptor  (ER), tissue sections
were incubated in citrate buffer, pH 6, at 95°C in a steamer for 35 min, followed
by incubation overnight at 4°C with primary antibodies. To detect endothelial
cells, tissue sections were digested with N-p-tosyl-L-phenylalanyl chloromethyl
ketone-trypsin (0.05%) for 28 min before overnight incubation at 4°C with rat
anti-mouse CD31 (2.5 	g/ml; BD Biosciences). The primary antibodies were
amplified with biotinylated anti-rat (CD31) or anti-rabbit (ER) immunoglob-
ulin G (Vector Laboratories) and detected using the Vectastain Elite ABC
reagent (Vector Laboratories) with 3,3-diaminobenzidine as the substrate.
CD31 staining was quantitated using NIH Image 1.61 software. To detect apop-
totic cells, tissue sections were stained using the ApopTag Plus peroxidase in situ
apoptosis detection kit according to the manufacturer’s instructions (Chemi-
con, Temecula, CA).
ELISAs. VEGF-A protein was measured using the murine VEGF Quantikine
enzyme-linked immunosorbent assay (ELISA) kit (R&D Systems) according to
the manufacturer’s instructions.
Real-time quantitative PCR (RQ-PCR). Total RNA was isolated from lung
tissue and tumors using the RNeasy extraction kit (QIAGEN). Quantitative
analysis of gene expression was obtained using the ABI 7300 sequence detection
system and TaqMan One-Step RT-PCR master mix reagents (Applied Biosys-
tems). PyV-MT mRNA was amplified using the following primers and probe:
forward primer, 5-AGCCCGATGACAGCATATCC-3; reverse primer, 5-GG
TCTTGGTCGCTTTCTGGA-3; Taqman probe, 5-CGGACCCCCCCAGAA
CTCCTGT-3. The murine VEGF-A primer pairs and probe were obtained from
Applied Biosystems. The transcript quantity in each RNA sample was normal-
ized to that of glyceraldehyde-3-phosphate dehydrogenase using the TaqMan
Pre-Developed assay reagent for rodents (Applied Biosystems).
Immunoprecipitation and immunoblotting. Frozen tumors were homogenized
at 4°C in T-PER tissue protein extraction reagent (Pierce Biotechnology, Inc.,
Rockford, IL), containing 1 mM sodium orthovanadate, and protease inhibitors
(Complete Mini; Roche Applied Science, Indianapolis, IN). Tissue culture cells
were solubilized at 4°C for 10 min in a 20 mM Tris buffer, pH 7.4, containing 0.14
M NaCl, 1% NP-40, 10% glycerol, 1 mM sodium orthovanadate, and protease
inhibitors. Nuclei were removed by centrifugation at 12,000  g for 10 min.
Aliquots of tissue or cell extracts containing equivalent amounts of protein were
incubated for 3 h at 4°C with antibodies and protein A Sepharose (Amersham
Biosciences) with constant agitation. The beads were washed three times in
extraction buffer. Laemmli sample buffer was added to the samples, which were
then incubated at 95°C for 4 min. Immune complexes, as well as aliquots of cell
and tumor extracts containing equivalent amounts of total protein, were resolved
by sodium dodecyl sulfate-polyacrylamide gel electrophoresis and transferred to
nitrocellulose filters.
For immunoblotting, the filters were blocked for 1 h with a 50 mM Tris buffer,
pH 7.5, containing 0.15 M NaCl, 0.05% Tween 20 (TBST), and 5% (wt/vol) dry
milk. The filters were incubated overnight at 4°C in the same buffer containing
primary antibodies. After three 10-min washes in TBST, the filters were incu-
bated for 1 h in blocking buffer containing horseradish peroxidase-conjugated
secondary antibodies. After three 10-min washes in TBST, proteins were de-
tected by enhanced chemiluminescence (Pierce). For RC-20 phosphotyrosine
immunoblots, the filters were blocked for 1 h with a 10 mM Tris buffer, pH 7.5,
containing 0.5 M NaCl, 0.1% Tween 20 (RC-20 buffer), and 2% (wt/vol) Car-
nation dry milk. The filters were washed briefly in RC-20 buffer and then incu-
bated overnight at 4°C in RC-20 buffer containing 3% (wt/vol) and a 1:500
dilution of the RC-20 antibody. After a wash, the filters were incubated for 1 h
in blocking buffer containing horseradish peroxidase-conjugated streptavidin and
the proteins were detected by enhanced chemiluminescence.
The following antibodies were used for immunoprecipitation or immunoblot-
ting: IRS-1 (Bethyl Labs); IRS-2 (immunoblot, Calbiochem, EMD Biosciences,
Inc., Darmstadt, Germany; immunoprecipitation, Bethyl Labs); phosphotyrosine
(RC-20; BD Biosciences, San Diego, CA; and 4G10; Upstate Biotechnology,
Charlottesville, VA); p85 (a generous gift from Alex Toker); 4-integrin subunit
(a generous gift from Arthur Mercurio); ER, IGF-1 receptor (IGF-1R) -sub-
unit, and PP2A (Y307) catalytic subunit (Santa Cruz Biotechnology, Santa Cruz,
CA); PP2A catalytic subunit (BD Biosciences); PTEN (Chemicon, Temecula,
CA); and cyclin D1 (Biosource, Camarillo, CA). All other antibodies were
purchased from Cell Signaling Technology, Inc. (Beverly, MA).
Cell lines, siRNA, and transfections. PyV-MT mammary tumor cell lines were
established as described previously (52). Small interfering RNA (siRNA) oligo-
nucleotides for Irs-1 and Irs-2 targeting were as follows: NNUAACCGGUUU
CGAAAGAGA (siIrs1 no. 1), NNAGCCGGUCCUCUCUUACUA (siIrs1 no.
2), NNGGCAGGACCUUCCCAGUAA (siIrs2 no. 1), and NNCUACACGCC
UAUCGCUAGA (siIrs2 no. 2). The Irs-1 siRNA oligonucleotides were com-
bined equally into one pool and transfected into PyV-MT tumor cells in OPTI-
MEM (Invitrogen) using Oligofectamine (Invitrogen) according to the
manufacturer’s recommendations. The final concentration for siRNA transfec-
tion was 400 nM. The Irs-2 siRNA oligonucleotides were transfected individually
into PyV-MT::Irs1/ tumor cells at a final concentration of 200 nM. Twenty-
four hours after transfection, the cells were incubated in Dulbecco’s modified
Eagle’s medium containing 0.1% bovine serum albumin for an additional 24 h.
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The luciferase control siRNA was obtained from Dharmacon Research, Inc.
(Lafayette, CO).
Statistics. For the densitometric analyses of immunoblots, the results were
compared using the Mann-Whitney U test, and the values are presented as
means 
 standard errors (SEM) for each group. Fisher’s exact test and Pearson
chi-square test were employed to test the significance of the incidence of lung
metastasis. The apoptotic rates were compared using Student’s t test. All statis-
tical analyses were carried out with SPSS 11.5 statistical software, and a P value
of 0.05 was considered statistically significant. Corresponding significance levels
are indicated in the figures.
RESULTS
Irs-1 expression is not required for PyV-MT-dependent
mammary tumor initiation and tumor growth. The PyV-MT
oncogene transforms cells by activating signaling molecules
that include PI3K, Shc, and Src family kinases (25, 79). The
molecular changes that occur during progression of mammary
tumors that develop in response to PyV-MT have been de-
FIG. 1. Analysis of Irs-1 involvement in PyV-MT mammary tumor development. (A) Female PyV-MT and PyV-MT::Irs1/ mice were
monitored for the age at which mammary tumors were first palpable. The mean age in days for palpable tumors (
 SEM) (P  0.05) is shown.
The number of mice analyzed for each genotype is indicated. (B) Female PyV-MT and PyV-MT::Irs1/ mice were analyzed for their total tumor
burden at 80 days of age. The mean tumor volume for each genotype (
 SEM) (P  0.05) is shown. The number of mice analyzed is indicated.
(C) Biochemical analysis of representative PyV-MT and PyV-MT::Irs1/ mammary tumors. Aliquots of mammary tumor extracts that contained
equivalent amounts of total protein were immunoblotted with antibodies specific for Irs-1, Irs-2, insulin receptor (IR) -subunit, IGF-1R -subunit,
cyclin D1, 4, or -actin. WT, PyV-MT mice; Irs1/, PyV-MT::Irs1/ mice. (D and E) Sections from PyV-MT (D) and PyV-MT::Irs1/
(E) tumors were stained with antibodies specific for ER. Inset, normal glands showing positive ER staining.
9340 MA ET AL. MOL. CELL. BIOL.
 o
n
 January 10, 2014 by W








scribed, and these tumors mimic key features of human breast
cancer (40). We have previously shown that Irs-1 and Irs-2 are
expressed in PyV-MT-derived mammary tumors and that Irs-2
expression is not required for PyV-MT-dependent mammary
tumor initiation or primary tumor growth (52). To assess if
Irs-1 is required for PyV-MT-dependent tumorigenesis, female
PyV-MT/ transgenic mice or transgenic mice that were null
for the Irs-1 allele (PyV-MT::Irs1/) were analyzed for mam-
mary tumor development. Mammary gland development is
normal in the absence of Irs-1 (37). Tumors were first detected
at similar ages in PyV-MT and PyV-MT::Irs1/ mice (Fig. 1A
and 2A and B). The total tumor burdens did not differ signif-
icantly between these mice at 80 days of age (Fig. 1B). Taken
together with our previous findings with PyV-MT::Irs2/mice,
our results demonstrate that expression of either Irs-1 or Irs-2
is sufficient for PyV-MT-dependent mammary tumor initiation
and growth and suggest that Irs-1 and Irs-2 are either func-
tionally redundant or do not contribute to early stages of tu-
mor development (52).
Characterization of Irs-1 null tumors. To determine if a loss
of Irs-1 expression influences the progression of PyV-MT-de-
rived mammary tumors from hyperplasia to invasive carci-
noma, we assessed specific markers that increase or decrease
during progression to late-stage disease in this model (40).
ER is expressed in normal mammary epithelial cells, and its
expression diminishes during tumor progression (11, 40, 71);
cyclin D1 expression increases during the progression from
hyperplastic lesions to late-stage carcinomas, which reflects the
increased mitotic indices of these poorly differentiated tumors
(40, 73). Both PyV-MT and PyV-MT::Irs1/ tumors were
negative for ER expression (Fig. 1D and E). Moreover, the
absence of Irs-1 did not alter the expression of cyclin D1 in
the mammary tumors (52) (Fig. 1C). These results support
the conclusion that Irs-1 is not required for progression to
malignancy, since overall tumor development was not delayed
in the absence of this docking protein. We evaluated the ex-
pression and activation of the IGF-1 and insulin receptors in
the tumors because they are upstream regulators of the IRS
proteins and have been implicated in breast cancer. Whereas
the IGF-1R was expressed at equivalent levels in the WT and
Irs1/ tumors, insulin receptor expression was reduced in the
absence of Irs-1 (Fig. 1C). However, we did not detect activa-
tion of these receptors in either of the tumor genotypes, sug-
gesting that other upstream regulators of IRS function are
responsible for activating the IRS proteins in PyV-MT-derived
tumors (data not shown) (38, 68, 70, 78, 81, 85). We also
assessed the expression of the 4 integrin subunit as a marker
of the epithelial content of the tumors and found equivalent
expression levels, supporting that the overall tumor/stromal
ratios were not altered by the loss of Irs-1 (48) (Fig. 1C). Total
Irs-2 expression did not increase significantly in PyV-MT::
Irs1/ tumors to compensate for the absence of Irs-1 (Fig.
FIG. 2. Histological characteristics of PyV-MT (A and C) and PyV-MT::Irs1/ (B and D) mammary tumors. (A and B) PyV-MT and
PyV-MT::Irs1/ mice at 24 and 25 days, respectively, the time for onset of palpable tumors. Inset, H&E-stained sections from the same mice
(magnification, 100). (C and D) Solid, nodular, high-grade tumors that lack glandular structure (magnification, 200).
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1C). Finally, PyV-MT expression was equivalent in the
PyV-MT and PyV-MT::Irs1/ tumors (data not shown).
Analysis of the PyV-MT and PyV-MT::Irs1/ tumors at the
earliest time of palpable detection revealed that the tumors
arose in a multifocal manner in both genetic backgrounds (Fig.
2A and B). High-grade tumors developed in both groups of
mice, with areas of solid tumor nests lacking significant glan-
dular structure and containing large, pleiotropic nuclei with
little cytoplasm (Fig. 2C and D). Invasion of tumor cells into
the surrounding stromal tissue was observed more frequently
in the PyV-MT::Irs1/ tumors than in the tumors from
PyV-MT mice (data not shown). These in vivo results are
consistent with our previously published findings demonstrat-
ing that Irs1/ mammary tumor cells are more invasive in
vitro in Matrigel invasion assays than wild-type mammary tu-
mor cells, and they support that loss of Irs-1 promotes invasive
potential (52). The histology and behavior of the PyV-MT::
Irs1/ tumors contrasts with the more well-differentiated
histology that we observed in the absence of Irs-2, suggest-
ing that Irs-1 may play a suppressive role in later stages of
tumor progression (52).
Loss of Irs-1 promotes mammary tumor metastasis in a
cell-autonomous manner. PyV-MT mammary tumors are char-
acterized by a high incidence of lung metastasis (24). To test
our hypothesis that Irs-1 regulates mammary tumor metastasis,
we microscopically screened five independent H&E-stained
sections of the lungs from each of the PyV-MT or
PyV-MT::Irs1/ mice. An increased incidence of lung metas-
tasis was observed for the PyV-MT::Irs1/ mice compared
with results for the PyV-MT mice at all time points examined
(75, 80, and 85 days). We expanded the number of mice at the
80-day time point, and the difference in metastasis was found
to be statistically significant (WT versus IRS-1/, P  0.001;
Fig. 3A). To quantify the differences in metastasis, PyV-MT
mRNA expression in the lungs of the 80-day mice was mea-
sured using real-time PCR. PyV-MT is not expressed in the
lungs of normal mice, and the amount of PyV-MT mRNA is a
measure of tumor burden in this tissue (52). A significantly
higher level of PyV-MT mRNA expression was measured in
the lungs from PyV-MT::Irs1/ mice than in the lungs from
PyV-MT mice (P  0.001; Fig. 3B). These results confirm that
Irs-1 deficiency increases mammary tumor metastasis.
The ability of tumors to grow and metastasize is influenced
by stromal cells and other factors in the tumor microenviron-
ment, as well as systemic conditions (82). Many stromal cells,
including fibroblasts, endothelial cells, and immune cells, ex-
press IRS-1, and the absence of IRS-1 protein in these diverse
cell types could influence tumor metastasis. To determine if
the impact of Irs-1 deficiency on metastasis is an intrinsic
property of the tumor cells in the PyV-MT::Irs1/ mice, the
FIG. 3. Analysis of Irs-1 involvement in PyV-MT mammary tumor metastasis. (A) Lungs from female PyV-MT and PyV-MT::Irs1/ mice were
sectioned and screened microscopically for the presence of metastatic lesions. Five representative sections from each lung were analyzed. The
percentage of mice that scored positively for metastatic lesions at each time point (75, 80, and 85 days) is shown (for WT versus Irs1/ results
at 80 days, P  0.001). (B) PyV-MT mRNA was amplified and quantified from the lungs of 80-day-old PyV-MT and PyV-MT::Irs1/ mice by
RQ-PCR. The data shown are the mean mRNA expression levels (
 SEM) from 16 mice of each genotype. (P  0.001.) (C) Mean tumor burden
(
 SEM) of PyV-MT and PyV-MT::Irs1/ tumors grown orthotopically in the mammary fat pads of female nu/nu mice. The number of mice
analyzed is indicated. (P  0.05.) (D) Lungs from mice with PyV-MT and PyV-MT::Irs1/ orthotopic tumors were sectioned and screened
microscopically for the presence of metastatic lesions. Five representative H&E sections from each lung were analyzed. The percentage of the mice
that scored positively for metastatic lesions is shown. (P  0.05.) WT, PyV-MT mice; Irs1/, PyV-MT::Irs1/ mice.
9342 MA ET AL. MOL. CELL. BIOL.
 o
n
 January 10, 2014 by W








ability of Irs1/ mammary tumor cells to develop tumors and
metastasize in an Irs1/ genetic background was examined.
When PyV-MT and PyV-MT::Irs1/ mammary tumor cells
were injected into the mammary fat pad of female nu/nu mice,
100% of the mice developed tumors. In contrast to the equiv-
alent growth rates observed with the transgenic null mice,
PyV-MT::Irs1/ tumors grew faster than PyV-MT tumors
when grown orthotopically, suggesting that loss of Irs-1 in the
stromal microenvironment may negatively influence tumor
growth. An increased incidence of lung metastasis was de-
tected for the mice with PyV-MT::Irs1/ tumors compared
with results for mice with PyV-MT tumors of an equivalent size
(Fig. 3C and D). These results demonstrate that the increased
metastasis observed in the transgenic PyV-MT::Irs-1/ mice
did not result from systemic or stromal alterations but was due
to an absence of Irs-1 expression in the mammary tumor cells.
Similar to the tumors from the knockout mice, both PyV-MT
and PyV-MT::Irs1/ orthotopic tumors were solid in overall
appearance, and the Irs1/ tumors had a greater frequency of
stromal invasion (Fig. 4). Taken together, our results suggest
that IRS-1 may have metastasis suppressor functions in breast
cancer.
Loss of Irs-1 expression enhances tumor angiogenesis by
increasing VEGF protein expression. One hallmark of meta-
static tumors is their ability to stimulate robust tumor angio-
genesis (26). To determine if the enhanced metastasis we ob-
served in the absence of Irs-1 corresponded to a stimulation of
angiogenesis, we assessed the microvascular density in the
PyV-MT::Irs1/ and PyV-MT tumors by staining for the en-
dothelial cell-specific marker CD31 (67). Tumor vascular den-
sities were significantly higher in PyV-MT::Irs1/ tumors than
in PyV-MT tumors, whether established in PyV-MT transgenic
mice or as orthotopic tumors in nu/nu mice (P  0.05 for both
transgenic and orthotopic tumors) (Fig. 4A to C).
FIG. 4. Analysis of tumor angiogenesis in PyV-MT and PyV-MT::Irs1/ mammary tumors. (A) PyV-MT and PyV-MT::Irs1/ tumors from
transgenic and nu/nu mice were stained with antibodies specific for CD31 to detect tumor angiogenesis. (B and C) Quantification of angiogenesis
in PyV-MT and PyV-MT::Irs1/ transgenic (B) or orthotopic (C) mammary tumors. The results shown are the mean area of CD31 staining (

SEM). The number of mice analyzed is indicated. Magnification, 400. (D and E) Quantification of VEGF-A protein levels in the tumors (D) or
serum (E) of PyV-MT and PyV-MT::Irs1/ transgenic mice. The data shown are the mean concentrations of VEGF-A (
 SEM). WT, PyV-MT
mice; Irs1/, PyV-MT::Irs1/ mice.
VOL. 26, 2006 IRS-1 FUNCTION IN METASTASIS 9343
 o
n
 January 10, 2014 by W








To address the mechanism by which angiogenesis was en-
hanced in Irs-1-deficient tumors, VEGF-A protein levels were
measured in tumors from PyV-MT or PyV-MT::Irs1/ mice
by ELISA. VEGF-A expression was significantly higher in
PyV-MT::Irs1/ tumors than in PyV-MT tumors (P  0.001)
(Fig. 4D). VEGF-A protein levels were also significantly ele-
vated in the serum of the PyV-MT::Irs1/ tumor-bearing
mice (P 0.001) (Fig. 4E). VEGF expression can be regulated
by both transcriptional and posttranscriptional mechanisms
(43, 45). To determine whether the increased protein levels in
the PyV-MT::Irs1/ mice resulted from enhanced mRNA
transcription, RQ-PCR was performed using primers that rec-
ognize all isoforms of VEGF-A. The level of VEGF-A mRNA
in the PyV-MT::Irs1/ tumors did not differ significantly from
the level of VEGF-A mRNA in the PyV-MT tumors, indicat-
ing that VEGF-A expression is increased at the posttranscrip-
tional level in the absence of Irs-1 (data not shown).
Activation of mTor signaling in Irs-1/ mammary tumors.
The fact that VEGF-A expression is increased in PyV-MT::
Irs1/ tumors in the absence of an increase in mRNA expres-
sion led us to hypothesize that VEGF expression may be con-
trolled through an increase in protein translation. To investi-
gate the mechanism by which VEGF translation could be
regulated, we examined the activation of mTor, a central reg-
ulator of the translational machinery (28). To do so, we eval-
uated the phosphorylation of mTor on serine-2448 (S2448) in
PyV-MT and PyV-MT::Irs1/ tumor extracts, because phos-
phorylation at this site is indicative of mTor activation (10, 30).
As shown in Fig. 5, phosphorylation of mTor S2448 was sig-
nificantly increased in PyV-MT::Irs1/ tumors compared with
results for PyV-MT tumors. To examine further if the mTor
pathway was activated at higher levels in the absence of Irs-1,
we assessed the activation status of two major downstream
effectors of mTor, p70-S6 kinase (S6K) and 4EBP1, both of
which are involved in regulating protein synthesis. S6K is phos-
phorylated on threonine-389 by mTor, and this phosphoryla-
tion event promotes full activation of the kinase to phosphor-
ylate the ribosomal protein S6 (56). 4EBP1 is phosphorylated
on multiple residues, of which threonine-70 is mTor dependent
(20). Phosphorylation of 4EBP1 promotes its dissociation from
the translation initiation factor eIF4E, thereby promoting cap-
dependent translation (21). Both S6K and 4EBP1 were phos-
phorylated at significantly higher levels in the PyV-MT::Irs1/
tumors than in the PyV-MT tumors, confirming that mTor-
dependent signaling is elevated in Irs-1-deficient tumors (Fig.
5). In addition, S6 phosphorylation was increased significantly
in the PyV-MT::Irs1/ tumors, providing evidence for en-
hanced S6K activation (Fig. 5).
Cell survival is increased in Irs-1-deficient mammary
tumors. In addition to its important role as a translational
FIG. 5. Evaluation of mTor activation and signaling in PyV-MT and PyV-MT::Irs1/ transgenic mammary tumors. Aliquots of tumor extracts
from PyV-MT and PyV-MT::Irs1/ mammary tumors containing equivalent amounts of total protein were immunoblotted with antibodies specific
for phosphoserine-2448 of mTor (mTor S2448), total mTor, phosphothreonine-389 of S6 kinase (S6K T389), total S6 kinase, phosphoserine-240/
244 of S6 (S6 S240/244), total S6, phosphothreonine-70 of 4EBP1 (4EBP1 T70), total 4EBP1, or -actin. For densitometry, n  12 for each
genotype. The relative levels of phosphorylation are shown in the graphs to the right of each immunoblot pair. WT, PyV-MT mice; Irs1/,
PyV-MT::Irs1/ mice.
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regulator, eIF4E has also been implicated in oncogenesis
through its contribution to survival signaling (72, 80). To
determine if eIF4E activity was increased in PyV-MT::Irs1/
tumors, we evaluated the phosphorylation of eIF4E on serine-
209. As shown in Fig. 6A, eIF4E phosphorylation was signifi-
cantly elevated in PyV-MT::Irs1/ tumors compared with
results for PyV-MT tumors. We also assessed the status of Akt
signaling in the tumors, because Akt is a central regulator of
survival signaling pathways and it is commonly activated in
many types of cancer (41, 44, 72, 77, 80). Moreover, Akt is an
upstream regulator of mTor function (31, 47). Akt activity is
regulated by phosphorylation on two key residues, serine-473
and threonine-308 (2, 63). Both residues were phosphorylated
at higher levels in PyV-MT::Irs1/ tumors than in PyV-MT
tumors (Fig. 6A). In addition, phosphorylation of GSK-3 on
serine-9, an Akt-dependent site, was also significantly in-
creased, confirming that Akt activity was enhanced in Irs-1-
deficient tumors (Fig. 6A) (13).
To evaluate directly if cell survival was increased in
PyV-MT::Irs1/ tumors, apoptosis was assessed in PyV-MT
and PyV-MT::Irs1/ tumor sections by ApopTag staining.
Although apoptotic cells were present in tumors from both
genetic backgrounds, the percentage of apoptotic cells was
markedly decreased in the PyV-MT::Irs1/ tumors (P 
FIG. 6. Absence of Irs-1 increases tumor cell survival. (A) Aliquots of tumor extracts from PyV-MT and PyV-MT::Irs1/ transgenic mammary
tumors containing equivalent amounts of total protein were immunoblotted with antibodies specific for phosphoserine-209 of eIF4E (eIF4E S209),
total eIF4E, phosphothreonine-308 of Akt (Akt T308), phosphoserine-473 of Akt (Akt S473), total Akt, phosphoserine-9 of GSK-3 (GSK3 S9),
total GSK-3, or -actin. For densitometry, n 12 for each genotype except for GSK-3 (n 11). The relative levels of phosphorylation are shown
in the graphs to the right of each immunoblot pair. (B and C) Terminal deoxynucleotidyltransferase-mediated dUTP-biotin nick end labeling
analysis of PyV-MT and PyV-MT::Irs1/ transgenic mammary tumors. (B) Representative images from PyV-MT and PyV-MT::Irs1/ mammary
tumors stained with Apoptag reagent are shown (magnification,400). (C) The percentages of ApopTag-positive nuclei in the tumor sections were
determined using the following formula: number of ApopTag-positive nuclei/total nuclei (P  0.01). n  20 fields (4 random fields from 5 tumors)
for each group (PyV-MT or PyV-MT::Irs1/ mice). WT, PyV-MT mice; Irs1/, PyV-MT::Irs1/ mice.
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FIG. 7. Irs-2-dependent signaling in the absence of Irs-1. (A) Aliquots of tumor extracts from PyV-MT and PyV-MT::Irs1/ transgenic
mammary tumors containing equivalent amounts of total protein were immunoblotted with antibodies specific for phosphotyrosine-307 of the
catalytic subunit of PP2A (PP2A Y307), total catalytic subunit of PP2A, or PTEN. Aliquots of tumor extracts were also immunoprecipitated with
an antiserum specific for IRS-2, and the immune complexes were immunoblotted with phosphotyrosine-specific antibodies (RC-20). The pTyr
immunoblots were subsequently stripped and reprobed with Irs-2-specific and p85-specific polyclonal antisera. (B) Densitometric analysis of
relative PP2A phosphotyrosine levels (n  12 for each genotype; P  0.05). (C) Densitometric analysis of relative PTEN expression (n  12 for
each genotype; P  0.05). (D) Densitometric analysis of p85 binding to Irs-2. (n  11 for each genotype; P  0.05). WT, PyV-MT mice; Irs1/,
PyV-MT::Irs1/ mice (E) PyV-MT tumor cells were transfected with either a control luciferase siRNA (Luc) or Irs-1-specific siRNAs (Irs-1).
Aliquots containing equivalent amounts of total protein were immunoblotted with antibodies specific for Irs-1, Irs-2, phosphosthreonine-389 of S6
kinase (S6K T389), total S6K, or -actin (upper panels). Aliquots of the cell extracts containing equivalent amounts of total protein were
immunoprecipitated with an Irs-2-specific antiserum and immunoblotted with phosphotyrosine-specific antibodies (4G10). The immunoblots were
subsequently stripped and reprobed with Irs-2- and p85-specific antibodies (lower panels). (F) PyV-MT::Irs1/ tumor cells were transfected with
either a control luciferase siRNA (Luc) or two different Irs-2-specific siRNAs (Irs-2 #1 and Irs-2 #2). Aliquots containing equivalent amounts of
total protein were immunoblotted with antibodies specific for Irs-2, Irs-1, phosphothreonine-389 of S6 kinase (S6K T389), or total S6K. WT,
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0.001) (Fig. 6B and C). Taken together, our results provide
evidence that Irs-1 deficiency triggers the activation of tumor
cell survival signaling pathways that may facilitate tumor cell
metastasis.
Irs-2 activation in the absence of Irs-1. IRS-1 contains mul-
tiple PI3K binding sites and can participate in the activation of
Akt and mTor in many model systems (51, 81). However, the
activation of these signaling pathways was increased when Irs-1
expression was abolished, which raises the question as to how
Akt and mTor activation are enhanced in the absence of Irs-1.
Reduced expression of PTEN, a lipid phosphatase that nega-
tively regulates PI3K signaling, or decreased activation of
PP2A, a serine-threonine phosphatase that negatively regu-
lates both Akt and S6K, would enhance Akt/mTor signaling
(49, 55). Mutation of PTEN has been reported to compensate
for the absence of IRS-1 in prostate carcinoma cells (59).
However, PTEN expression and PP2A activation were not
significantly different in the PyV-MT and PyV-MT::Irs1/
tumors (Fig. 7A to C). In contrast to the increased metastasis
that we observed in PyV-MT::Irs1/ mammary tumors, we
have previously demonstrated that Irs-2-deficient mammary
tumors have a reduced metastatic potential (52). We hypoth-
esized that Akt and mTor signaling could be elevated in Irs-
1-deficient tumors through increased Irs-2 function. In support
of this mechanism, Irs-2 was more heavily tyrosine phos-
phorylated in the PyV-MT::Irs1/ tumors than in the
PyV-MT tumors (Fig. 7A). Importantly, the amount of p85
regulatory subunit of PI3K that coimmunoprecipitated with
Irs-2 was significantly higher in PyV-MT::Irs1/ tumors, indi-
cating that Irs-2-dependent PI3K activation was increased (P
 0.05) (Fig. 7A and D).
To investigate further the connection between Irs-1 and
Irs-2 expression and to determine if Irs-1 directly influences
Irs-2 expression and function, we transiently knocked down
Irs-1 expression in PyV-MT mammary tumor cells using
siRNA oligonucleotides. Irs-2 expression increased in tumor
cells when Irs-1 expression was suppressed (Fig. 7E). Irs-2
tyrosine phosphorylation and association with PI3K and acti-
vation of the downstream effector S6K also increased when
Irs-1 expression was downregulated, as we had observed with
the PyV-MT::Irs1/ mammary tumors. To investigate the
contribution of Irs-2 to the enhanced activation of Akt/mTor
signaling pathways in the absence of Irs-1, we suppressed Irs-2
expression transiently in Irs1/ tumor cells. When Irs-2 ex-
pression was knocked down to wild-type levels in the
PyV-MT::Irs1/ tumor cells, S6K activation was also restored
to the level observed in wild-type cells (Fig. 7F). These in vitro
results support that Irs-2 compensates for the loss of Irs-1 and
in doing so enhances the activation of signaling pathways that
promote tumor metastasis.
Irs-1 is inactivated in metastatic tumors. The results from
our PyV-MT tumor studies demonstrate that mammary tumor
cells have a greater metastatic potential in the absence of Irs-1
expression. To investigate the physiological relevance of our
findings for human breast cancer metastasis, we assessed
whether Irs-1 expression or function was suppressed in meta-
static mammary tumors. Irs-1 expression was maintained in
PyV-MT metastatic tumors at levels equivalent to or higher
than those in nonmetastatic (PyV-MT::Irs2/) tumors. IRS-1
function can be negatively regulated by serine phosphoryla-
tion, which prevents tyrosine phosphorylation and blocks the
interaction of IRS-1 with downstream effectors, effectively in-
hibiting downstream signaling (22). To investigate if Irs-1 func-
tion is inactivated in metastatic tumors, we examined the phos-
phorylation status of several serine residues in Irs-1. Irs-1 was
consistently phosphorylated on all of the serine residues that
we examined in the metastatic tumors (Fig. 8). In contrast,
serine phosphorylation of Irs-1 in the nonmetastatic tumors
was sporadic, and none of the serine residues was consistently
phosphorylated in the tumors we examined. To determine the
effect of serine phosphorylation on Irs-1 function in the met-
astatic tumors, Irs-1 tyrosine phosphorylation was assessed.
The level of Irs-1 tyrosine phosphorylation in the metastatic
tumors was markedly lower than that observed for Irs-1 in the
nonmetastatic tumors, demonstrating that Irs-1 function was
suppressed in metastatic tumors (Fig. 8).
FIG. 8. Irs-1 is inactivated in metastatic PyV-MT mammary tu-
mors. Aliquots of tumor extracts from PyV-MT and PyV-MT::Irs2/
mammary tumors containing equivalent amounts of total protein were
immunoblotted with antibodies specific for total Irs-1 or phospho-
serine Irs-1 (S302, S307, S636/S639, S789, and S1101) (upper panels).
Aliquots of tumor extracts from WT and Irs2/ transgenic mammary
tumors containing equivalent amounts of total protein were immuno-
precipitated with an Irs-1-specific antiserum and then immunoblotted
with phosphotyrosine-specific antibodies. The immunoblots were sub-
sequently stripped and reprobed with Irs-1-specific antibodies (lower
panels). The numbers below indicate the relative levels of Irs-1 ty-
rosine phosphorylation in each tumor. WT, PyV-MT mice; Irs2/,
PyV-MT::Irs2/ mice.
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In this study, we demonstrate that mammary tumor metas-
tasis is enhanced in the absence of Irs-1. Specifically, mammary
tumor latency and growth were not altered in Irs-1-deficient
mouse mammary tumor virus–PyV-MT transgenic mice com-
pared with those for wild-type littermates, but lung metastasis
increased significantly in the absence of Irs-1 expression. The
increased metastatic potential of Irs-1-deficient tumor cells
was maintained when these cells were grown orthotopically in
the mammary fat pad of nu/nu mice, supporting a cell-auton-
omous function for Irs-1 in mammary tumor metastasis. Acti-
vation of Irs-2 was enhanced in Irs-1-deficient mammary tu-
mors, a novel finding that contributes to a growing body of
evidence that Irs-2 is a positive regulator of tumor progression.
Irs-1-deficient tumors are characterized by enhanced activa-
tion of the Akt and mTor signaling pathways, as well as by
increased VEGF expression and microvascular density. Impor-
tantly, we demonstrate that Irs-1 function is suppressed in
wild-type metastatic mammary tumors. This result validates
our findings from the Irs-1-deficient mice and supports the
novel hypothesis that IRS-1 has metastasis suppressor func-
tions for breast cancer.
A novel and unexpected finding from our study is that Irs-2
activity increased in Irs-1-deficient mammary tumors. This ac-
tivation of Irs-2, as indicated by increased tyrosine phosphory-
lation and association with PI3K, was coincident with an en-
hanced activation of Akt and mTor. Knock-down of Irs-2
restored the activation of these signaling molecules to wild-
type levels, supporting that Irs-2 is responsible for their en-
hanced activation in the absence of Irs-1. Our observed in-
crease in Irs-2 function was not anticipated, because activation
of mTor signaling has been shown to inhibit IRS expression
and function (18, 69). Negative feedback regulation of the IRS
proteins was first demonstrated in insulin-dependent signaling,
and this feedback pathway is essential for regulating insulin
sensitivity and glucose homeostasis (1, 39, 74). Serine phos-
phorylation of the IRS proteins by multiple kinases, including
the mTor-dependent p70-S6 kinase, can interfere with their
function by targeting these docking proteins for inactivation
and/or proteasomal degradation (22). Inactivation occurs ei-
ther through inhibition of recruitment to upstream regulatory
receptors or through disruption of interactions with down-
stream effectors (22). In tumors that arise from mutations in
pathways that impede mTor signaling, such as the TSC1 or
TSC2 genes, p70-S6 kinase is constitutively active (27, 69).
These tumors grow quite large but rarely progress to invasive
carcinoma, because both IRS-1 and IRS-2 are degraded in
response to S6 kinase-mediated phosphorylation (46, 69). In
contrast to the benign nature of the TSC1/2 mutant tumors, we
observed that Irs-1-deficient tumors, which have increased
mTor signaling, progress more rapidly to metastasis. We hy-
pothesize that the reason for this discrepancy is that Irs-2 is
resistant to negative feedback regulation, which leads to en-
hanced function in the Irs-1-deficient tumors.
The fact that Irs-2 activation is enhanced in Irs-1-deficient
tumors that are more metastatic substantiates our previous
finding that Irs-2 is a positive regulator of mammary tumor
progression. Specifically, we demonstrated that mammary tu-
mor metastasis was significantly diminished in the absence of
Irs-2 (52). One mechanism by which IRS-2 is likely to contrib-
ute to tumor metastasis is through its ability to regulate cell
motility. Irs-2-deficient mammary tumor cells are less invasive,
and Irs-1-deficient tumor cells, which signal exclusively
through Irs-2, are more invasive, both in vitro and in vivo, than
their wild-type counterparts (52). IGF-1 promotes cell motility
and invasion in breast carcinoma cell lines that express IRS-2
but not in cell lines that express only IRS-1 (14, 33, 86). Similar
influences of the IRS proteins on motility have been found in
other types of tumor cell lines. Specifically, IRS-2-dependent
signaling promotes cell motility and invasion in neuroblastoma
and mesothelioma cells, while expression of IRS-1 in LNCaP
prostate carcinoma cells decreases motility (29, 34, 59). In
addition to being more motile, mammary tumor cells that
express only Irs-2 are also resistant to stress-induced apoptosis.
Therefore, a second mechanism by which IRS-2-dependent
signaling contributes to metastasis is by regulating survival
signaling pathways (52). In fact, enhanced IRS-2 signaling
could explain the discrepancy between our data showing that
IRS-1 deficiency promotes tumor cell survival and previous
studies reporting that “knock-down” of IRS-1 expression in
MCF-7 breast carcinoma cells increases apoptosis. MCF-7
cells express predominantly IRS-1, and when IRS-1 is sup-
pressed in these cells, IRS-2 is not present to compensate for
the loss (9, 53). However, in PyV-MT mammary tumor cells,
like ER human breast carcinoma cells, Irs-2 is expressed and
its function is enhanced, which leads to an increased activation
of PI3K, a major upstream regulator of signaling pathways that
regulate both cell survival and invasion. Given that both IRS-1
and IRS-2 can recruit and activate PI3K, other factors must
influence the outcomes of PI3K signaling downstream of these
two adaptor proteins, or IRS-1 would be capable of promoting
metastasis to the same extent as IRS-2. Distinct intracellular
compartmentalization of IRS-1 and IRS-2 can impact the func-
tional outcome of signals transmitted through these adaptor
proteins (17). Furthermore, differential sensitivities of IRS-1
and IRS-2 to negative feedback regulation could alter the
longevity and intensity of signals initiated through each pro-
tein, modifying cellular responses to PI3K activation and im-
pacting tumor metastasis.
Our conclusion that IRS-1 impedes metastasis, which was
obtained using Irs-1-deficient mice, implies that mechanisms
exist in tumors to suppress IRS expression or function to pro-
mote progression. Indeed, a major observation from our study
is that Irs-1 is expressed in metastatic wild-type mammary
tumors but that it is phosphorylated on serine residues and
inactivated. This finding raises the novel hypothesis that IRS-1
functions as a metastasis suppressor in breast cancer. Taken
together with our previous work showing that IRS-2 promotes
metastasis, it appears that the IRS proteins are prime candi-
dates for prognostic markers for breast cancer progression.
Interestingly, however, neither IRS-1 nor IRS-2 has been iden-
tified as a marker of tumor progression or metastasis by mi-
croarray analysis, supporting our conclusion that changes in
IRS function occur primarily at the level of protein expression
or activation and not through changes in gene expression. To
date, IRS-2 protein expression in human breast tumors has not
been evaluated, and only a few studies have directly assessed
IRS-1 protein expression. One study reported strong down-
regulation of IRS-1 in grade 3, poorly differentiated breast
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tumors, confirming our prediction for a positive correlation
between low IRS-1 and poor prognosis (64). However, sepa-
rate studies have reported that high IRS-1 expression is pre-
dictive of a greater incidence of recurrence and a decreased
patient survival rate (36, 60). A caveat to these last reports that
is highlighted by our own data is that overall expression of
IRS-1 or IRS-2 may not reflect the activation status of these
docking proteins, and IRS-1 may be expressed, but not active,
in these tumors with a poor prognosis. In future studies, it will
be important to identify specific serine or tyrosine phosphory-
lation events that can be used to assess functional activity of
these proteins in tumors to evaluate the prognosis more accu-
rately.
Our molecular analysis of Irs-1-deficient tumors revealed
that they express significantly more VEGF-A than do wild-type
tumors and that VEGF-A is increased in the serum of Irs-
deficient tumor-bearing mice. These tumors also exhibited a
significant increase in microvessel density, which is consistent
with increased VEGF expression. The possibility that in-
creased VEGF-A expression and microvessel density in re-
sponse to loss of Irs-1 promote progression is supported by
numerous studies on human breast tumors that have corre-
lated these parameters with disease progression and negative
outcome, as well as by recent transgenic studies in which over-
expression of VEGF-A in the mammary gland resulted in
increased tumor metastasis in mice (12, 54, 65, 75). VEGF
contributes to metastasis in a paracrine manner by promoting
tumor angiogenesis and also acts in an autocrine manner to
support the survival of metastatic tumor cells outside of their
normal microenvironment, where exogenous stimuli are absent
and intrinsic survival mechanisms are required (4, 5, 65). Given
our finding that mTor activation is enhanced in Irs-1/ tu-
mors and the fact that mTor is a key regulator of protein
translation, it is feasible that mTor-dependent VEGF transla-
tion is stimulated in the absence of Irs-1. In fact, mTor-depen-
dent regulation of VEGF-A translation was recently reported
for tumors that develop in response to overexpression of the
Her2/Neu oncogene (35). mTor is emerging as an essential
regulator of tumorigenesis and progression in many types of
cancer, including breast cancer, and the notion that protein
translation can be a regulatory checkpoint for tumor progres-
sion is gaining support (23, 57). Indeed, many oncogenes,
growth regulatory genes, and survival genes that are associated
with cancer are regulated at the level of translation initiation
(45, 61). Thus, it is likely that in addition to VEGF-A, other
proteins that play important roles in promoting tumor metas-
tasis are up-regulated in a translation-dependent manner in
response to increased mTor activity when IRS-1 is inactivated
in tumors.
The relevancy of our studies for human breast cancer is
highlighted by the fact that mouse mammary tumors that de-
velop in response to the PyV-MT oncogene in an Irs-1-defi-
cient background are phenotypically similar to aggressive, ad-
vanced human breast tumors that are associated with poor
patient prognosis. Elevated levels of VEGF-A in tumors and
sera correlate with a poor prognosis for breast cancer patients
(12, 19, 62). Akt activation is positively associated with disease
progression and occurs early, at the ductal carcinoma in situ
stage, and persists throughout tumor development (7). mTor
and its downstream effector p70-S6 kinase are both expressed
and activated at high levels in invasive human breast carcino-
mas, and both of these signaling molecules are associated with
an increased risk for disease recurrence (7, 35, 76, 87). Expres-
sion of the translation initiator eIF4E is also upregulated in
human cancers, including breast, and it has been linked to
metastasis (8, 58). In the absence of Irs-1, mouse mammary
tumors exhibit increased activity of all of these signaling mol-
ecules, confirming that at the molecular level, loss of Irs-1
closely mimics the progression of human breast cancer to met-
astatic disease.
In summary, we have established that suppression of Irs-1
promotes mammary tumor metastasis, and we provide evi-
dence that Irs-1 is inactivated in metastatic tumors. Taken
together with our previous study demonstrating that loss of
Irs-2 impedes mammary tumor metastasis, we now have strong
evidence that IRS-1 and IRS-2 play distinct roles in breast
cancer metastasis. Our novel findings support the possibility
that IRS activity, rather than expression, may be a valuable
predictive indicator of metastasis in human breast cancer.
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